SDZ 208912
Alternative Names: HDC 912; MAR 327; SDZ HDC 912; SDZ MAR 327Latest Information Update: 15 Jun 1998
At a glance
- Originator Novartis
- Class
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 15 Jun 1998 Discontinued-II for Psychotic disorders in European Union (Unknown route)
- 15 Jun 1998 Discontinued-II for Psychotic disorders in USA (Unknown route)
- 18 Jun 1997 Phase-II clinical trials for Psychotic disorders in European Union (Unknown route)